This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Crombet, T. Articles by Lage, A. Search for Related Content PubMed PubMed Citation Articles by Crombet, T. Articles by Lage, A. Social Bookmarking                            What's this?

Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination With Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer Patients

From the Center of Molecular Immunology; National Institute of Oncology; Institute of Pharmacy and Food, University of Havana; Center for Chemistry and Pharmacy, Havana, Cuba; and London Regional Cancer Center, London, Ontario, Canada

Address reprint requests to Tania Crombet, MD, Center of Molecular Immunology, Clinical Immunology Department, PO Box 16040, Havana 11600, Cuba; e-mail: Taniac{at}ict.cim.sld.cu

PURPOSE: To evaluate safety and preliminary efficacy of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy (RT) in unresectable head and neck cancer patients. Secondary end points were the measurement of h-R3 serum levels and the assessment of the potential mechanisms of antitumor effect on patient biopsies. Anti-idiotypic response to h-R3 was assessed. To predict pharmacologic effect, a mathematical model for antibodies recognizing antigens expressed in tumors and normal tissues was built.

PATIENTS AND METHODS: Twenty-four patients with advanced carcinomas of the head and neck received six once-weekly infusions of h-R3 at four dose levels in combination with RT. Pretreatment tumor biopsies were obtained to evaluate epidermal growth factor receptor expression as an enrollment criterion. Second biopsies were taken to evaluate the proliferative activity and angiogenesis in comparison with the pretreatment samples. Patient serum samples were collected to measure h-R3 levels and anti-idiotypic response.

RESULTS: The combination of h-R3 and RT was well tolerated. Antibody-related adverse events consisted in infusion reactions. No skin or allergic toxicity appeared. Overall survival significantly increased after the use of the higher antibody doses. Immunohistochemistry studies of tumor specimens before and after treatment revealed that antitumor response correlated with antiproliferative and antiangiogenic effect. One patient developed antibodies to h-R3. The mathematical model predicted that the maximum difference between the area under the curve in tumors and normal tissues is reached when the antibody has intermediate affinity.

CONCLUSION: h-R3 is a well-tolerated drug that may enhance radiocurability of unresectable head and neck neoplasms.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. M. Egloff, M. E. Rothstein, R. Seethala, J. M. Siegfried, J. R. Grandis, and L. P. Stabile Cross-Talk between Estrogen Receptor and Epidermal Growth Factor Receptor in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., November 1, 2009; 15(21): 6529 - 6540. [Abstract] [Full Text] [PDF]

				S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer J Natl Cancer Inst, October 7, 2009; 101(19): 1308 - 1324. [Abstract] [Full Text] [PDF]

				A. Talavera, R. Friemann, S. Gomez-Puerta, C. Martinez-Fleites, G. Garrido, A. Rabasa, A. Lopez-Requena, A. Pupo, R. F. Johansen, O. Sanchez, et al. Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation Cancer Res., July 15, 2009; 69(14): 5851 - 5859. [Abstract] [Full Text] [PDF]

				J. Cruz, A Ocana, E Del Barco, and A Pandiella Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer Ann. Onc., March 1, 2007; 18(3): 421 - 430. [Abstract] [Full Text] [PDF]

				D. G.P. Allan Nimotuzumab: Evidence of Clinical Benefit Without Rash Oncologist, October 1, 2005; 10(9): 760 - 761. [Full Text] [PDF]

				J. Kim, R. M. Adam, and M. R. Freeman Trafficking of Nuclear Heparin-Binding Epidermal Growth Factor-like Growth Factor into an Epidermal Growth Factor Receptor-Dependent Autocrine Loop in Response to Oxidative Stress Cancer Res., September 15, 2005; 65(18): 8242 - 8249. [Abstract] [Full Text] [PDF]

				M.-C. Etienne-Grimaldi, S. Pereira, N. Magne, J.-L. Formento, M. Francoual, X. Fontana, F. Demard, O. Dassonville, G. Poissonnet, J. Santini, et al. Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients Ann. Onc., June 1, 2005; 16(6): 934 - 941. [Abstract] [Full Text] [PDF]

				J. Baselga and C. L. Arteaga Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer J. Clin. Oncol., April 10, 2005; 23(11): 2445 - 2459. [Abstract] [Full Text] [PDF]

				P. M. Harari Promising new advances in head and neck radiotherapy Ann. Onc., January 1, 2005; 16(suppl_6): vi13 - vi19. [Abstract] [Full Text] [PDF]

				E. Vokes Current treatments and promising investigations in a multidisciplinary setting Ann. Onc., January 1, 2005; 16(suppl_6): vi25 - vi30. [Abstract] [Full Text] [PDF]

				P. Carter, L. Smith, and M. Ryan Identification and validation of cell surface antigens for antibody targeting in oncology Endocr. Relat. Cancer, December 1, 2004; 11(4): 659 - 687. [Abstract] [Full Text] [PDF]